Background: Peroxisome proliferator-activated receptor-gamma (PPAR-␥) agonists are used as anti-diabetic drugs, and their pleiotrophic action has been reported to improve endothelial function leading to cardioprotective effects. In this study we evaluated the long-term effect of pioglitazone on cardiac function in diabetic patients after percutaneous coronary intervention (PCI) by drug-eluting stent (DES).
Summary
Background: Peroxisome proliferator-activated receptor-gamma (PPAR-␥) agonists are used as anti-diabetic drugs, and their pleiotrophic action has been reported to improve endothelial function leading to cardioprotective effects. In this study we evaluated the long-term effect of pioglitazone on cardiac function in diabetic patients after percutaneous coronary intervention (PCI) by drug-eluting stent (DES).
Methods and results:
We investigated 54 diabetic patients who received PCI using a sirolimus-eluting stent. We excluded cases of acute myocardial infarction. They were divided into two groups: Group C received only conventional therapy (n = 26) and Group P received additionally pioglitazone 15 mg/day (n = 28). The left ventricular ejection fraction (LVEF) was measured by left ventriculography and analyzed before and 8 months after PCI. In Group C, LVEF did not change significantly: 55.6% vs. 56.7%, before and after PCI respectively (p = 0.58). However, pioglitazone significantly improved LVEF: 54.4% vs. 60.0% (p = 0.014). Multiple linear regression analysis showed that LVEF was significantly related to pioglitazone therapy (p = 0.037). In particular, the combination of pioglitazone and statin improved LVEF ( LVEF 9.6% with vs. 2.2% without statin).
Introduction
Percutaneous coronary intervention (PCI) is one of the first-line therapies for coronary artery disease (CAD), but it might not lead to improvement of the long-term outcome. In particular, cardiac function remains depressed in diabetics even after relief of ischemia by PCI [1] . Recently, PCI with a drugeluting stent (DES), a sirolimus-eluting stent (SES), has been widely employed with excellent results [2, 3] . Although DES has reduced the rate of restenosis after PCI, restenosis has been reported to occur in the range from 6.0% to 8.2% in non-diabetics and from 10.1% to 17.6% in diabetics [4, 5] . Impaired endothelial regeneration at the site of DES implantation is considered to be responsible and it may cause late stent thrombosis [6, 7] . The long-term outcomes of PCI with DES remain to be elucidated especially in diabetic patients.
On the other hand, the peroxisome proliferatoractivated receptor-gamma (PPAR-␥) agonist class, thiazolidinedione (TZD), has been shown to decrease the incidence of cardiovascular events in diabetic patients [8] , but its effect on long-term cardiac function needs to be evaluated.
In this study, we administered one of the TZDs, pioglitazone, to diabetic patients with CAD treated with DES and evaluated its effects on cardiac function.
Patients
Fifty-nine diabetic patients with CAD were included. In this study, all patients met one or more of the following criteria: (1) a fasting blood glucose level ≥126 mg/dL; (2) a casual blood glucose level of 200 mg/dL; (3) glycated hemoglobin (HbA1c) ≥6.5% or higher; (4) diabetic type on a 75-g oral glucose tolerance test; and (5) receiving therapy for diabetes mellitus.
All patients had CAD, either stable angina pectoris (Canadian Cardiovascular Society class I-IV), unstable angina (Braunwald class I-III B or C), recent myocardial infarction, or previously documented myocardial infarction. CAD was proven by coronary angiography (CAG) with coronary artery stenosis means ≥51% in diameter. The patients with myocardial infarction were proven to have viable myocardium by left ventriculography (LVG), stress myocardial scintigraphy, or cardiac magnetic resonance imaging (MRI).
The patients received PCI with DES and were followed over 8 months in the standard manner. Patients were excluded if they had: (1) myocardial infarction within the previous 24 h; (2) restenosis, target lesion revascularization (TLR) or target vessel revascularization (TVR) during follow-up; (3) a new lesion at other coronary artery during followup; (4) significant valvular heart disease; (5) dilated cardiomyopathy; and (6) severe renal dysfunction requiring hemodialysis. At baseline, cardiac catheterization was performed which included LVG, and CAG as well as a pressure tracing study. From LVG, left ventricular end-diastolic volume index (EDVI), left ventricular end-systolic volume index (ESVI), and global left ventricular ejection fraction (LVEF) were calculated in area-length method from RAO view by other radiologists.
Methods
Catheterization was repeated 8 months after PCI. EDVI, ESVI, and LVEF values were obtained and compared between the two groups. Other clinical data were also obtained at baseline and 8 months after PCI and compared between the two groups.
In addition, we performed multiple linear regression analysis for change in LVEF ( LVEF) with age, gender, smoking, medications [angiotensinconverting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), nitrate agents, ␤ blockers, Ca antagonists, statins, pioglitazone, and antidiabetic agents other than pioglitazone], lesion site, baseline LVEF, baseline EDVI, and HbA1c, as independent variables. 
Statistical analysis
Numerical data are expressed as mean ± S.D. All statistical analysis was performed using the JMP program version 5.0.1J for Macintosh (SAS Institute, Cary, NC, USA). Variables were compared before and after PCI using the paired t-test, with a two-sided significance level of p < 0.05. We used the unpaired t-test in the comparison between group C and P and used the one-way analysis of variance (ANOVA) in comparison among groups.
Results

Patient background
In total, 59 diabetic patients underwent SES implantation and LVG analysis both at baseline and follow-up catheterization. Of these, two patients in Group C required additional PCI to another vessel due to progression of stenosis at follow-up, and 1 had progression of valvular heart disease in Group P. 1 patient had dilated cardiomyopathy in Group C. TVR was noted in 1 patient in Group C. In the remaining 54 diabetic patients, we analyzed the clinical characteristics and the long-term outcomes. They consisted of 28 who were treated with pioglitazone: Group P, and 26 without pioglitazone treatment: Group C. There were no side effects of pioglitazone 15 mg/day, such as leg edema, or heart failure.
The background of the patients is shown in Table 1 . There were no significant differences in age, gender, diagnosis, risk factors (hypertension, hyperlipidemia, smoking), a history of myocardial infarction, or medication. Blood pressure and heart rate are shown in Table 2 . There were also no significant differences in blood pressure and heart rate between the two groups. Table 2 shows the changes in the fasting total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C), and HbA1c levels during this study. The baseline HbA1c and TG levels showed small These data show the mean ± S.D. BP, blood pressure; HR, heart rate; TC, total cholesterol; TG, triglyceride; HDL-C, HDLcholesterol; LVG, left ventriculograms; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; EF, ejection fraction.
Laboratory findings
differences between the two groups, but they were not significant. TC and HDL-C were not significantly different between the two groups. The HbA1c levels decreased (p = 0.024) and the HDL-C levels increased (p = 0.044) significantly after pioglitazone treatment, while conventional therapy resulted in no change in these parameters.
CAG findings
The cardiac catheterization findings are shown in Table 3 . In Group P, culprit lesions involving the left circumflex coronary artery were more frequent (p = 0.032). However, there were no significant differences in other lesions. There were also no marked differences in the number of treated vessels between the two groups.
Follow-up of LVEF
LVEF before and after PCI are shown in Fig. 1 . In Group C, there was no significant increase after treatment (55.6% at baseline vs. 56.7% at 8 months' follow-up, p = 0.58). However, in Group P, LVEF significantly increased (54.4% vs. 60.0%, p = 0.014), These data show the mean ± S.D. LAD, left anterior descending artery; Cx, left circumflex coronary artery; RCA, right coronary artery; LMT, left main trunk; ACS, acute coronary syndrome; CTO, chronic total occlusion.
suggesting improvement in cardiac function by pioglitazone.
The results of multiple linear regression analysis in 54 diabetic patients are shown in Table 4 . Baseline LVEF (p = 0.0017), pioglitazone administration (p = 0.037), and the absence of RCA lesion (p = 0.030) correlated with LVEF. There was no correlation between LVEF and other parameters. In addition, the effect of combination therapy with pioglitazone and a statin is shown in Fig. 2 . There were no significant differences in baseline LVEF among the four groups (p = 0.103). Only combination therapy with pioglitazone and statin significantly improved LVEF after PCI (51.5% at baseline vs. 61.1% at 8 months' follow-up, p = 0.0066), and the absolute increase in LVEF ( LVEF) was +9.6% in the combination therapy group. The LVEF of the other three groups did not change significantly.
Discussion
The present study showed that low-dose pioglitazone improved cardiac function after DES in diabetic patients and such a beneficial effect was not observed in the patients followed without pioglitazone (Group C). All patients were free from restenosis. By the results of multiple linear regression analysis, improved LVEF significantly correlated with baseline LVEF, non-RCA lesion, and pioglitazone treatment. Although ACE inhibitor, ARB, and statin alone have already been reported to improve LV dysfunction, this is not the case in diabetic patients. Combined therapy of pioglitazone and statin was most impressive (Fig. 2) . Pioglitazone is the first oral anti-diabetic agent that has been demonstrated to improve the hard endpoints (all causes of mortality, non-fatal myocardial infarction, and stroke) for secondary prevention after myocardial infarction [8] . TZDs are assumed to play multiple actions: improvement in endothelial dysfunction [9] , increase in endothelial progenitor cells (EPC), enhancement of EPC differentiation, survival, and function [10] [11] [12] , enhancement of angiogenesis [13] , suppression of inflammation [14] , and increase in the plasma adiponectin level [15] . TZDs have also been shown to up-regulate the PI3K-Akt signal and down-regulate MAPK, leading to endothelial repair [16] . The precise mechanism for improved cardiac function in diabetic patients is speculative, but pleiotrophic effects of pioglitazone seem to be involved [17] [18] [19] [20] , and seem to explain the bene- ficial effect on cardiac function as shown by the present study.
However, previous studies have not shown improvement in LVEF, as assessed by echocardiography [21] in patients who did not undergo revascularization. Others reported that pioglitazone prevented in-stent restenosis but did not affect LVEDVI in diabetic patients who received bare metal stent implantation after acute myocardial infarction [22] . High-dose pioglitazone did not change LV remodeling after coronary ligation in mice [17] . There were some discrepancies between the previous studies and our study, and we showed that patients on low-dose pioglitazone demonstrated improved cardiac function especially when it was combined with statins. The combination therapy of TZDs and statin has already been shown to reduce the size of infarcted myocardial foci [23] , and they may play additive effects in improving cardiac function after DES. Both drugs might relieve endothelial dysfunction and oxidative stress after DES implantation. Since intra-myocardial capillary density has been shown to be decreased in diabetic patients compared to non-diabetics [24] , the effect of either drug on inducing angiogenesis might result in favorable long-term results. Microcirculation distal to the site of SES might be improved as endothelial function improves. Otherwise, the direct effect of sirolimus [25] may impair endothelial function and suppress LV function even after relief of ischemia.
In addition, pioglitazone may promote endothelial regeneration via mobilization of EPC, and prevent late stent thrombosis. Thus, in PCI using DES, combination therapy with pioglitazone and statin should be administered to diabetic patients to achieve secondary prevention and improve cardiac function.
Study limitations
This study has some limitations. First, this was an unblinded, non-randomized, cohort study. Although we used ''Group C'' as the historical control, we did not change the strategy of PCI using SES between two groups. Second, LVG analysis was performed from the RAO view, so mild regional wall motion abnormality might have been undetected. However, we could obtain a global function of LV in the most accurate way so far.
Conclusion
Pioglitazone, a PPAR-␥ agonist, improved cardiac function after PCI with DES in diabetic patients. The combination therapy of pioglitazone and statin can be indicated in diabetic patients after PCI.
